NEW PRECLINICAL DATA

$Biomea Fusion (BMEA.US)$ New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared to semaglutide alone

Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose

Ex vivo human islet experiments previously presented in October, showed that icovamenib enhanced the activity of glucagon-like peptide-1 (GLP-1)-based therapies, leading to substantial increase in insulin secretion

Topline data from the COVALENT-111 study showed that 12 weeks of daily icovamenib in patients uncontrolled on a GLP-1-based therapy (n=10) led to an HbA1c reduction of 0.84% at week 26

Further data will be presented during the upcoming J.P. Morgan Conference January 13-15, 2025